This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) is funded by the National Institutes of Health and is being conducted at 6 universities across the country. The Investigators are interested in learning more about HIV-associated neurological disease and will collect detailed medical, laboratory, psychological and psychiatric histories and evaluations over the next 5 years on approximately 1600 people at the 6 sites. This information will help them understand if and how anti-retroviral medications (HAART) affect the complication or prevention of neurological disease and impairment (such as dementia or peripheral neuropathy) in those infected with HIV. Researchers are also interested in the effect HAART has on the metabolic changes that often occur, i.e., loss of or redistribution of body fat. A secondary concern is how HAART and psychiatric medications interact. Following screening, some participants will go through a group of tests one time only (called cross-sectional or Stage II). Other participants will be asked to undergo testing every 6 months (longitudinal or Stage III). Basic testing will include neurological examination, neuropsychological evaluation, psychiatric history, blood collection, and a lumbar puncture. Additional testing may include nerve conduction studies and MRI. There is reimbursement for time and inconvenience. Some of the testing will take place in the GCRC exam rooms either at the ACCRP clinic or on the 5th floor of the John Sealy Hospital.
Showing the most recent 10 out of 465 publications
